PF-06826647

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	2

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003999-39-NO (EUCTR)	17/08/2020	29/04/2020	A placebo-controlled study followed by an open label treatment to evaluate the safety and efficacy o ...	A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EX ...	moderate to severe ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;T ...	Product Name: PF-06826647 Product Code: PF-06826647 INN or Proposed INN: PF-06826647	Pfizer Inc., 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: yes Male: yes	202	Phase 2	United States;United Arab Emirates;Qatar;Saudi Arabia;Hong Kong;Slovakia;Morocco;Spain;Ukraine;Irela ...
2	NCT04209556 (ClinicalTrials.gov)	June 30, 2020	1/12/2019	A Study To Evaluate The Safety And Efficacy Of PF-06826647In Participants With Moderate To Severe Ul ...	A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EX ...	Ulcerative Colitis	Drug: PF-06826647100 mg QD;Drug: PF-06826647300 mg QD;Drug: PF-06826647600 mg QD;Drug: Placebo;Drug: ...	Pfizer	NULL	Recruiting	18 Years	75 Years	All	202	Phase 2	United States

First Previous1Next Last